Curasight begins phase 1 trial of uTREAT in glioblastoma
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Active Biotech to receive US patent for tasquinimod formulation
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
Made Scientific enters manufacturing partnership with Cellergy Therapeutics
Novartis' Itvisma granted US FDA approval for spinal muscular atrophy treatment
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management